NAD+ asa rheostat governing endothelial senescent phenotype switching via CD38-mediated paracrine depletion and intracellular NAMPT buffering

Hypothesis

Endothelial senescence bifurcates into pro‑inflammatory and anti‑inflammatory states based on a NAD+ threshold set by the balance between intracellular NAMPT‑driven synthesis and extracellular CD38‑mediated consumption. When NAD+ falls below a critical level, eNOS becomes uncoupled, ROS rises, and the anti‑inflammatory program is reinforced; above the threshold, NAMPT‑fuelled glycolysis sustains p38 MAPK/NF‑κB signaling, driving a pro‑inflammatory SASP. Thus NAD+ is not merely a by‑product but a rheostat that actively chooses the senescent phenotype.

Mechanistic Model

• Intracellular NAD+ pool is buffered by NAMPT, which is upregulated by oncogenic RAS or metabolic stress, feeding glycolysis and supporting p38 MAPK/NF‑κB activity that fuels the inflammatory SASP (2).
• Paracrine CD38 secreted by senescent endothelial cells (or immune cells) converts extracellular NAD+ to ADPR, depleting the NAD+ available to neighboring cells (1).
• Falling NAD+ reduces the activity of NAD+‑dependent deacetylases (SIRT1/2) and ADP‑ribosyltransferases, leading to decreased eNOS coupling and increased ROS (4).
• Low ROS/SIRT1 signaling favors transcription of anti‑inflammatory genes (e.g., IL‑10, TGF‑β) and stabilizes the non‑inflammatory senescent state, whereas high NAD+ sustains NF‑κB driven ICAM‑1/VCAM‑1 expression (3).

Testable Predictions

1. Threshold effect: Manipulating intracellular NAD+ levels across a range (using graded NMN or FK866) will produce a bimodal distribution of ICAM‑1high vs. ICAM‑1low endothelial cells, with a sharp transition at a definable NAD+ concentration.
2. CD38 blockade in co‑cultures of senescent and naïve endothelial cells will rescue NAD+ in bystanders, suppress eNOS uncoupling, and shift the bystander phenotype toward the pro‑inflammatory SASP if intracellular NAMPT remains active.
3. SIRT1 activation (via SRT2104) will mimic low NAD+ conditions, promoting the anti‑inflammatory senescent phenotype even when NAD+ is pharmacologically elevated.
4. Genetic knockout of CD38 in senescent endothelial cells will reduce paracrine NAD+ consumption, increase NAD+ in neighboring cells, and increase the proportion of ICAM‑1high cells.

Experimental Approach

• In vitro: Human umbilical vein endothelial cells (HUVECs) induced to senesce by low‑dose doxorubicin or oncogenic RAS. Measure intracellular NAD+ (enzymatic assay), extracellular CD38 activity, eNOS coupling (NO/DHE ratio), and surface ICAM‑1/VCAM‑1 (flow cytometry). Apply NMN, FK866, CD38 neutralizing antibody, and SIRT1 agonist in matrix.
• In vivo: Use endotheliocyte‑specific CD38 knockout mice crossed with a p16‑3MR senescence reporter. Challenge with angiotensin‑II infusion to induce endothelial senescence. Assess aortic NAD+ levels, eNOS uncoupling (DHE fluorescence), ICAM‑1 expression (immunofluorescence), and neutrophil adhesion (intravital microscopy). Compare wild‑type vs. knockout.
• Readouts: Flow cytometry for bimodal ICAM‑1 distribution, western blot for phosphorylated p38, acetylated p65 (SIRT1 target), and nitrotyrosine (ROS marker). Statistical analysis to identify NAD+ concentration at which the phenotype switches.

Falsifiability

If graded NAD+ manipulation fails to produce a clear bimodal ICAM‑1 response, or if CD38 blockade does not alter bystander NAD+ levels or phenotype distribution, the hypothesis that NAD+ acts as a rheostat deciding senescent endothelial fate would be refuted. Conversely, consistent threshold‑dependent switching would support the model.